Monteris Medical Founders to Receive Pioneer in Technology Award
Founders Mark G. Torchia and Richard Tyc, are the 2020 recipients of the Pioneer in Technology Award by The Society for Brain Mapping & Therapeutics (SBMT).
Completion of Study Enrolment of Implandata’s Extraocular Eye Pressure Sensor for Continual Glaucoma Monitoring
This first-in-human clinical study is conducted to validate the suprachoroidally placed EYEMATE-SC sensor implant for continual monitoring of intraocular pressure (IOP). The lead investigator Prof. Dr. med. Peter Szurman from Eye Sulzbach at Knappschaft Hospital Saar, Germany asserts: “The eye pressure sensor is pleasantly small and easy to implant, so most patients undergoing glaucoma surgery are eligible for such a pressure sensor. This enables glaucoma patients for the first time to monitor their own eye pressure at any time. It will improve the safety for glaucoma patients and significantly reduce the risk of blindness due to glaucoma.”
Kitakyushu General Hospital Completes First Surgical Procedures with the Senhance Surgical System
Kitakyushu General Hospital, a hospital in southwestern Japan, completed its first surgical procedures using the Senhance® Surgical System. The first patients were treated by Dr. Naoki Nagata, President of Kitakyushu General Hospital, and team across general and colorectal minimally invasive surgical procedures.
CorTechs Labs Presents Findings on the Creation of Machine Learning Models to Aid Early, Accurate Diagnosis of MS at ACTRIMS 2020
CorTechs Labs evaluated the performance of these models for identifying MS subjects and studied the differences of feature importance selected by the models based on whole and specific age range data.
Stimwave and Nevro Reach Settlement In Patent Infringement Lawsuit
As part of the settlement, Stimwave has agreed to cease commercialization of all high frequency spinal cord stimulation systems, globally, in exchange for dismissal of the lawsuit with no damages assessed. The settlement pertains exclusively to spinal cord stimulation (SCS) and does not affect in any way Stimwave’s commercialization of its peripheral nerve stimulation (PNS) products for chronic pain management.